Literature DB >> 25339661

Helping themselves: optimal virus-specific CD4 T cell responses require help via CD4 T cell licensing of dendritic cells.

Matthew R Olson1, Shirley G K Seah2, Jolie Cullen1, Marie Greyer1, Kathryn Edenborough1, Peter C Doherty3, Sammy Bedoui1, Andrew M Lew2, Stephen J Turner4.   

Abstract

Although CD4(+) T cell help (Th) is critical for inducing optimal B cell and CD8(+) T cell responses, it remains unclear whether induction of CD4(+) Th responses postinfection are also dependent on CD4(+) T cell help. In this study, we show that activation of adoptively transferred Th cells during primary influenza A virus (IAV) infection enhances both the magnitude and functional breadth of endogenous primary IAV-specific CD4(+) T cell responses. This enhancement was dependent on CD154-CD40-dependent dendritic cell licensing and resulted in a greater recall capacity of IAV-specific CD4(+) and CD8(+) T memory responses after heterologous IAV infection. These data suggest that engaging pre-existing CD4 responses at the time of priming may be a strategy for improving cellular immunity after vaccination.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25339661     DOI: 10.4049/jimmunol.1303359

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Modulation of Host Immunity by the Human Metapneumovirus.

Authors:  Pablo F Céspedes; Christian E Palavecino; Alexis M Kalergis; Susan M Bueno
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

2.  Th22 Cells Form a Distinct Th Lineage from Th17 Cells In Vitro with Unique Transcriptional Properties and Tbet-Dependent Th1 Plasticity.

Authors:  Maximilian W Plank; Gerard E Kaiko; Steven Maltby; Jessica Weaver; Hock L Tay; Wei Shen; Mark S Wilson; Scott K Durum; Paul S Foster
Journal:  J Immunol       Date:  2017-01-18       Impact factor: 5.422

Review 3.  Innate and adaptive T cells in influenza disease.

Authors:  Simone Nüssing; Sneha Sant; Marios Koutsakos; Kanta Subbarao; Thi H O Nguyen; Katherine Kedzierska
Journal:  Front Med       Date:  2018-01-20       Impact factor: 9.927

Review 4.  Development of cross-protective influenza a vaccines based on cellular responses.

Authors:  Peter Christiaan Soema; Elly van Riet; Gideon Kersten; Jean-Pierre Amorij
Journal:  Front Immunol       Date:  2015-05-15       Impact factor: 7.561

5.  Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses.

Authors:  Nicola L Bird; Matthew R Olson; Aeron C Hurt; Christine M Oshansky; Ding Yuan Oh; Patrick C Reading; Brendon Y Chua; Yilun Sun; Li Tang; Andreas Handel; David C Jackson; Stephen J Turner; Paul G Thomas; Katherine Kedzierska
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

6.  NADPH Oxidase 1 Is Associated with Altered Host Survival and T Cell Phenotypes after Influenza A Virus Infection in Mice.

Authors:  Amelia R Hofstetter; Juan A De La Cruz; Weiping Cao; Jenish Patel; Jessica A Belser; James McCoy; Justine S Liepkalns; Samuel Amoah; Guangjie Cheng; Priya Ranjan; Becky A Diebold; Wun-Ju Shieh; Sherif Zaki; Jacqueline M Katz; Suryaprakash Sambhara; J David Lambeth; Shivaprakash Gangappa
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

7.  IL-15 supports the generation of protective lung-resident memory CD4 T cells.

Authors:  T M Strutt; K Dhume; C M Finn; J H Hwang; C Castonguay; S L Swain; K K McKinstry
Journal:  Mucosal Immunol       Date:  2017-11-29       Impact factor: 7.313

8.  CXCR6-Deficiency Improves the Control of Pulmonary Mycobacterium tuberculosis and Influenza Infection Independent of T-Lymphocyte Recruitment to the Lungs.

Authors:  Anneliese S Ashhurst; Manuela Flórido; Leon C W Lin; Diana Quan; Ellis Armitage; Sebastian A Stifter; John Stambas; Warwick J Britton
Journal:  Front Immunol       Date:  2019-03-07       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.